IL112766A0 - Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m - Google Patents

Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Info

Publication number
IL112766A0
IL112766A0 IL11276695A IL11276695A IL112766A0 IL 112766 A0 IL112766 A0 IL 112766A0 IL 11276695 A IL11276695 A IL 11276695A IL 11276695 A IL11276695 A IL 11276695A IL 112766 A0 IL112766 A0 IL 112766A0
Authority
IL
Israel
Prior art keywords
oncostatin
endothelial cell
methods
cell proliferation
effector functions
Prior art date
Application number
IL11276695A
Other languages
English (en)
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/335,399 external-priority patent/US5202116A/en
Application filed by Oncogen filed Critical Oncogen
Publication of IL112766A0 publication Critical patent/IL112766A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL11276695A 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m IL112766A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/335,399 US5202116A (en) 1989-04-10 1989-04-10 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US50448690A 1990-04-04 1990-04-04
IL9405595 1990-04-04

Publications (1)

Publication Number Publication Date
IL112766A0 true IL112766A0 (en) 1995-05-26

Family

ID=26989684

Family Applications (7)

Application Number Title Priority Date Filing Date
IL112768A IL112768A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
IL9405590A IL94055A (en) 1989-04-10 1990-04-09 Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption
IL11276690A IL112766A (en) 1989-04-10 1990-04-09 Pharmaceutical preparations containing oncostatin M intended for increased fibrinolysis and thrombolysis
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m
IL11276695A IL112766A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276895A IL112768A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276795A IL112767A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Family Applications Before (4)

Application Number Title Priority Date Filing Date
IL112768A IL112768A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
IL9405590A IL94055A (en) 1989-04-10 1990-04-09 Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption
IL11276690A IL112766A (en) 1989-04-10 1990-04-09 Pharmaceutical preparations containing oncostatin M intended for increased fibrinolysis and thrombolysis
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11276895A IL112768A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276795A IL112767A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Country Status (10)

Country Link
EP (1) EP0422186B1 (xx)
JP (4) JPH04502769A (xx)
AT (1) ATE174223T1 (xx)
CA (1) CA2028825A1 (xx)
DE (1) DE69032816T2 (xx)
DK (1) DK0422186T3 (xx)
ES (1) ES2124690T3 (xx)
GR (6) GR1002178B (xx)
IL (7) IL112768A (xx)
WO (1) WO1990012585A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
CA2055122A1 (en) * 1990-11-13 1992-05-14 Robert I. Grove Methods for stimulating ldl uptake and ldl receptor expression
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
AU3737893A (en) * 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
JP3490443B2 (ja) * 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
KR20010042288A (ko) 1998-03-31 2001-05-25 블레어 큐. 퍼거슨 신생혈관 형성 질환의 영상화용 약제
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2003295401B2 (en) * 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
ES2342529B1 (es) 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity

Also Published As

Publication number Publication date
IL112768A (en) 1998-06-15
DK0422186T3 (da) 1999-08-16
ES2124690T3 (es) 1999-02-16
IL112767A0 (en) 1995-05-26
GR900100278A (en) 1991-09-27
GR920100459A (el) 1994-03-31
JPH1028595A (ja) 1998-02-03
IL94055A0 (en) 1991-01-31
GR1002182B (en) 1996-04-30
GR1002178B (en) 1996-04-30
GR920100458A (el) 1994-03-31
ATE174223T1 (de) 1998-12-15
GR920100455A (el) 1994-03-31
JPH04502769A (ja) 1992-05-21
GR920100457A (el) 1994-03-31
IL112766A (en) 1996-06-18
GR1002187B (en) 1996-04-30
WO1990012585A1 (en) 1990-11-01
JPH1029948A (ja) 1998-02-03
GR1000968B (el) 1993-03-16
CA2028825A1 (en) 1990-10-11
GR920100456A (el) 1994-03-31
DE69032816D1 (de) 1999-01-21
EP0422186A4 (en) 1993-09-15
IL112768A0 (en) 1995-05-26
IL94055A (en) 1995-11-27
GR1002186B (en) 1996-04-30
IL112767A (en) 1998-01-04
JPH1029949A (ja) 1998-02-03
GR1002185B (en) 1996-04-30
EP0422186A1 (en) 1991-04-17
DE69032816T2 (de) 1999-07-29
EP0422186B1 (en) 1998-12-09

Similar Documents

Publication Publication Date Title
IL112767A0 (en) Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
ZA9810444B (en) Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
IL112585A (en) N-terminally chemically modified G-CSF and analogs process for their preparation and pharmaceutical compositions containing them
FR2679251B1 (fr) Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
ZA943464B (en) Vascular endothelial growth factor 2
TW225532B (xx)
HU902288D0 (en) Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
BG100829A (en) Benzothiophene, benzofuran and indolethiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of hiv
ZA967137B (en) Use of aminoadamantane compounds as immunoregulators
AU5198693A (en) A method of increasing adenosine excretion
PT916666E (pt) 3-alquiloxi- ariloxi- ou arilalquiloxi-benzo¬b|tiofeno-2-carboxamidas como inibidores de adesao celular
GB8917323D0 (en) Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
ZA932830B (en) A novel anti-neoplastic cytokine
ZA88830B (en) Treatment of disease
EP0353910A3 (en) Human interferon-gamma, process for preparing said human interferon-gamma, and its use
MX9602996A (es) Benzotiofeno, benzofurano e indolo-tiazepinones, oxazepinones y diazepinones como inhibidores de la adhesion celular y como inhibidores de vih.
IL80300A (en) Mitogenic tetradecapeptide homologs of human thrombin b
MX9800686A (es) Nueva proteina hmw humana mp52s.